Newport Board Group partner Bob Hickey was recently quoted on a key healthcare industry web site, Medical Device and Diagnostic Industry, in an article about the purchase of a wearables technology firm, Zephyr Technology, by Covidien, a global medical devices company.
The transaction marks Covidien’s, and perhaps any traditional medical technology firm’s, first investment in wearable medical devices and diagnostics.
Bob Hickey Talks About The Future of Wearable Medical Devices
Wearable computing devices—including the much publicized Google Glass, a wearable computer with an optical head-mounted display--are among the hottest sectors in the technology world. The tech industry is full of reports that other major players like Apple will soon launch products in this sector.
The piece about the Zephyr acquisition quotes Bob’s view on the importance of remote monitoring to patient care:
An expert in the medical device industry said that Covidien's acquisition underscores the importance of remote monitoring in the care of patients amid a changing healthcare landscape.
"I think we are emerging into a world that is moving toward remote care and remote monitoring where technologies like this will be part of the enabling system," said Bob Hickey, partner, Newport Board Group, a strategic consulting and business advisory firm. "A mosaic is developing. Pieces of different technology are going to be integrated into the care delivery of patients."
Bob’s healthcare background spans start ups to global firms and includes almost 20 years with Johnson & Johnson in various senior management roles including serving as CEO of SyntheMed, Inc., a publicly-traded company that develops and markets surgical implants derived from biomaterials.
If you would like to connect with Bob Hickey to talk more about healthcare innovations and technologies, click the link below.
More articles by Bob Hickey:
About the Author
Bob Hickey has a diverse background in general management roles ranging from start-ups to large corporations. He served as CEO and a member of the Board of Directors at SyntheMed, Inc., a publicly-traded company that develops and markets surgical implants derived from biomaterials.Bob led t the clinical and regulatory development program that resulted in the FDA approval of the company's key product; raised $30 million of equity financing and established an international distribution network, among other accomplishments. Learn more or contact Bob Hickey here.
